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Abstract
γ-Secretase is a membrane-embedded aspartyl protease complex central in biology and medicine. 
How this enzyme recognizes transmembrane substrates and catalyzes hydrolysis in the lipid 
bilayer is unclear. Inhibitors that mimic the entire substrate transmembrane domain and engage the 
active site should provide important tools for structural biology, yielding insight into substrate 
gating and trapping the protease in the active state. Here we report transmembrane peptidomimetic 
inhibitors of the γ-secretase complex that contain an N-terminal helical peptide region that 
engages a substrate docking exosite and a C-terminal transition-state analog moiety targeted to the 
active site. Both regions are required for stoichiometric inhibition of γ-secretase. Moreover, 
enzyme inhibition kinetics and photoaffinity probe displacement experiments demonstrate that 
both the docking exosite and the active site are engaged by the bipartite inhibitors. The solution 
conformations of these potent transmembranemimetic inhibitors are similar to those of bound 
natural substrates, suggesting these probes are preorganized for high-affinity binding and should 
allow visualization of the active γ-secretase complex, poised for intramembrane proteolysis, by 
cryo-electron microscopy.
Graphical Abstract
γ-Secretase is a membrane-embedded aspartyl protease complex, with presenilin as the 
catalytic component,1 that hydrolyzes >90 known substrates,2–3 including the amyloid 
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precursor protein (APP) of Alzheimer’s disease and the Notch family of developmental 
signaling receptors. How this enzyme recognizes substrate transmembrane domains and 
carries out intramembrane proteolysis has been mysterious. Advances in cryo-electron 
microscopy paved the way to the first detailed structure of the ~230 kDa complex,4 
comprised of membrane proteins nicastrin, Aph-1 and Pen-2 along with presenilin. Most 
recently, structures of γ-secretase bound to Notch and APP substrates were reported,5–6 
providing important insights into substrate recognition. Nevertheless, the active site was 
disabled through mutagenesis, and the substrates were artificially crosslinked to presenilin. 
To date, the enzyme has not been trapped in its active state, and the lateral gating pathway of 
substrate into the active site remains unclear.
To address this problem, we aimed to develop substrate TMD mimetics as chemical probes 
for structural analysis of γ-secretase. These probes would trap the active enzyme at the 
transition state, allowing acquisition of high-resolution snapshots of substrate recognition 
with the protease poised for catalysis of TMD cleavage. We and others previously reported 
peptidomimetic transition-state analogue inhibitors (TSAs) of γ-secretase7–9 and use of 
these as probes for active site binding pockets.10–13 We have also reported helical peptide 
inhibitors (HPIs) that interact with a substrate docking exosite distinct from but proximal to 
the active site.14–15 We recently demonstrated that substrate TMD is sufficient for high-
affinity binding (Km < 100 nM)16 and therefore sought peptide-based inhibitors that would 
mimic the entire TMD and interact with both the docking site and the active site. 
Specifically, we worked to couple an HPI to a TSA through a variable linker (Fig. 1).
We chose a pentapeptide TSA with a hydroxyethylurea moiety and spanning residues P2 
through P3’ (TSA 1, see Table 1) that showed optimal activity in a cell-based assay for 
inhibiting γ-secretase-mediated production of the amyloid β-peptide (Aβ) from APP 
substrate.13 Residues P1’, P2’, and P3’ are especially important for substrate recognition and 
processing.17 In a purified enzyme assay, TSA 1 displayed an IC50 of 41 nM (Table 1). HPI 
2, containing helix-inducing α-aminoisobutyric acid (Aib) residues spaced apart to arrange 
the Aib residues along one face of the helix and presenting APP TMD residues to the 
enzyme along the rest of the helix,14 showed comparable activity (IC50 of 58 nM). We 
aimed to connect these two compounds between HPI C-terminus and TSA N-terminus with 
intervening linkers of varying lengths. Coupling in this manner, with the TSA on the C-
terminus of the TMD mimetic, is consistent with γ-secretase initially cleaving APP TMD on 
the C-terminal end three residues from the membrane-cytosol interface.18–19 To access these 
highly hydrophobic HPI-TSA conjugates, we generated hydroxyethylurea-containing 
tripeptide building blocks suitably protected for solid-phase peptide synthesis (Scheme S1). 
All synthesized peptides were purified to >95% by HPLC.
HPI-TSA conjugate 3, containing no linker moiety, displayed an IC50 of 53 nM, with no 
improvement in potency compared to either TSA 1 or HPI 2 alone (Table 1). Inserting a 4-
atom hydro-carbon linker gave 4, with an IC50 of 12 nM, while inserting a 6-atom spacer 
provided 5, with an IC50 of 10 nM, increasing potency 4-to-6-fold over TSA 1 or HPI 2. 
Finally, extending the linker to a 10-atom spacer gave 6, the most potent compound in the 
series, with an IC50 of 0.8 nM. This compound essentially titrates the enzyme, as the assay 
was done with 1 nM of purified γ-secretase.
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Control peptide 7 containing TSA 1 and the 10-atom spacer alone was roughly twice as 
potent as 1, showing that the linker contributes to binding to the enzyme. Control peptide 8, 
with the transition-state mimicking isostere in 6 replaced with an amide bond, showed >20-
fold reduced potency (IC50 = 18 nM). Moreover, MS analysis revealed that 8 was 
hydrolyzed by γ-secretase between the two Phe residues, validating the correct registry of 
binding and appropriate placement of the transition-state isostere in 6 (Fig. S1). When two 
internal L-Val residues of the potent 6 were exchanged with D-Val in compound 9, 
inhibitory potency decreased nearly eight-fold, presumably due to disruption of the helical 
conformation in this part of the TMD mimetic. A similar series of TMD mimetics were also 
synthesized with P2’ in the TSA moiety as Ala in place of Leu (10–16, Table S2), leading to 
identification of another stoichiometric inhibitor 16 (IC50 + 0.5 nM).
To confirm helicity of the HPI portion of 6 and disruption of this helix in 9, we performed 
2D NMR experiments. Rotating frame nuclear Overhauser effect spectroscopy (ROESY) 
reveals spatial proximity between NH↔NH and CαH↔NH protons in peptides. NH↔NH 
cross-peak intensities between residues 5↔6, 6↔7, 7↔8 were found to be higher in 6 than 
in 9, suggesting that the HPI region of 6 is more helical than that of 9 (Fig. S3). In the 
CαH↔NH region of 6, medium-range NOEs indicated coupling between distal residues 
(e.g., 1↔4, 2↔5, 4↔7, 6↔9; Fig. S4). Such cross couplings are absent in 9, again 
suggesting that the HPI region of 6 is more helical than that of 9. Thus, the integrity of the 
helical peptide moiety is apparently important for maintaining stoichiometric inhibition of 
γ-secretase.
Enzyme inhibition kinetics experiments were carried out for the two most potent HPI-TSA 
inhibitors (6 and 16). Both compounds showed noncompetitive inhibition (Figs. S5, S6). 
Both HPI 2 and TSA 17 (identical to 1 but with C-terminal methyl ester) likewise showed 
noncompetitive inhibition on their own (Fig. S7), as has been reported before with other γ-
secretase inhibitors.20 To determine whether the HPI and TSA moieties of 6 bind both 
docking and active sites on the enzyme, we performed cross-competition assays between 
two inhibitors.21 In these experiments, TSA 17 and HPI 2 did not compete with each other 
for binding, consistent with binding to distinct sites (active site for 17, docking site for 2)
(Fig. 2a). However, HPI-TSA inhibitor (6) competed with both TSA 17 and HPI 2 for 
binding (seen as parallel lines in Fig. 2b,c), indicating that 6 occupies both docking site and 
active site on the enzyme.
To verify this, we performed competition experiments with biotinylated photoaffinity probes 
for γ-secretase:15, 22 active-site-directed photoprobe TSA-Bpa-Bt based on TSA 1 and 
docking-site-directed photoprobes HPI-Bpa-Bt based on HPI 2. We have previously shown 
that 10-residue HPIs do not inhibit labeling of presenilin by TSA-Bpa-Bt, whereas TSAs do 
not inhibit labeling by 10-residue HPI-Bpa-Bt.15 Solubilized lysates from γ-secretase-
expressing human embryonic kidney 293 cells were incubated with each photoprobe in the 
presence and absence of the HPI-TSAs inhibitors and irradiated at 350 nM. Photolabelled 
proteins were pulled down with streptavidin beads, and the ~32 kDa band of the presenilin-1 
(PS1) N-terminal fragment (NTF) subunit was detected by immunoblot. Lack of competition 
between TSA and HPI was confirmed (Fig. 3a, b). Decreased photolabelling of the PS1 NTF 
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γ-secretase subunit by either probe was observed in the presence of HPI-TSA inhibitors 6 
and 16 (Fig. 3c,d, lane 1 vs 2 and 3) and in a concentration-dependent manner (Fig. S8). 
These results indicate that stoichiometric inhibitors 6 and 16 interact with both active and 
docking sites on γ-secretase, as they compete with the binding of both photoprobes.
Finally, the conformation of these new inhibitors, determined using NMR constraints for 6, 
resembles the bound conformation of substrate in the new cryo-EM structures (Fig. 4), with 
a helical N-terminal region and an unfolded or extended C-terminal region. Thus, the new 
potent HPI-TSA inhibitors appear to be preorganized for ideal binding to γ-secretase and 
trapping the enzyme complex as it would be when poised for intramembrane proteolysis. 
Moreover, after initial substrate proteolysis, γ-secretase carries out successive 
carboxypeptidase trimming in intervals of three amino acids of the N-terminal cleavage 
product that contains most of the substrate TMD,19 and this trimming activity is deficient in 
γ-secretase complexes with Alzheimer-causing presenilin mutations.23–24 These new TMD 
mimetic inhibitors, with three P’ residues in the TSA moiety, should capture the enzyme as 
it would carry out this trimming reaction. Cryo-EM analysis of these new probes in complex 
with γ-secretase is in progress. Variations on these TMD inhibitors are under development 
to trap other stages of substrate interaction with γ-secretase (e.g., lateral gating, initial 
proteolysis). Together, these conjugates should be important structural probes for gaining 
insights into the mechanism of intramembrane proteolysis by γ-secretase and how mutations 
in the enzyme cause Alzheimer’s disease.
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Figure 1. Design of inhibitors that mimic the transmembrane domain of γ-secretase substrates.
Helical peptide inhibitors (HPIs) directed to the substrate docking exosite were conjugated 
through a variable linker to transition-state analogue inhibitors (TSAs) directed to the active 
site. Presenilin (blue-grey) and other components of the γ-secretase complex (outlined) are 
shown schematically in the absence and presence of a hybrid HPI-TSA inhibitor.
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Figure 2. Cross-competition kinetic experiment between two inhibitors.
(a) TSA 17 and HPI 2 at [2] = 0 nM (●), 10 nM (●), 20 nM (●), and 40 nM (●). These 
two inhibitors do not compete, as lines converge near the x-axis. (b) TSA 17 and HPI-TSA 6 
at [6] = 0 nM (●), 0.2 nM (●), 0.4 nM (●), and 0.8 nM (●). Parallel lines indicate cross-
competition. (c) HPI 2 and HPI-TSA 6 at [6] = 0 nM (●), 0.2 nM (●), 0.4 nM (●), and 0.8 
nM (●). Again, parallel lines indicate cross-competition, and HPI-TSA 6 competes with 
both TSA 17 and HPI 2.
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Figure 3: Competition of HPI-TSAs with photoaffinity probes for γ-secretase.
Photoprobes TSA-Bpa-Bt (left) and HPI-Bpa-Bt (right) covalently label presenilin-1 (PS1) 
N-terminal fragment (NTF) at the active site and docking site, respectively. (a) TSA (17) but 
not HPI (2) decreased the labelling of PS1 NTF by the TSA photoprobe. (b) HPI (2) but not 
TSA (17) decreased the labelling PS1 NTF by the HPI photoprobe. (c, d). HPI-TSAs 6 and 
16 decreased labelling by both TSA photoprobe (c) and HPI photoprobe (d).
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Figure 4: Solution conformation of designed HPI-TSA conjugate 6 resembles that of APP TMD 
substrate bound to γ-secretase.
NMR constraints were used to determine low-energy conformations of 6. The top 10 
conformers are shown as sticks, with the conformer closest to that of the bound substrate in 
blue. Structure rendered in Pymol using PDB file 6IYC for bound APP substrate, shown as 
surface outline. Transition-state mimicking hydroxyl group (red) of 6 overlaps with the 
scissile amide bond in the extended region of APP substrate when the helical moiety is 
aligned with the helical region of bound APP substrate.
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